{"content":"<li class=\"n-box-item date-title\" data-end=\"1576645199\" data-start=\"1576558800\" data-txt=\"Monday, December 23, 2019\">Tuesday, December 17, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3526976\" data-ts=\"1576629157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526976-pg-and-e-reaches-1_6b-wildfire-settlement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E reaches $1.6B wildfire settlement</a></h4><ul><li>Pacific Gas and Electric Company (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <a href=\"https://seekingalpha.com/pr/17731091-pg-and-e-submits-comprehensive-multi-party-settlement-agreement-to-cpuc-related-to-2017-and\" target=\"_blank\">submits </a>a multiparty settlement agreement to the California Public Utilities Commission related to the 2017 and 2018 wildfires in Northern California.</li><li>The settlement agreement proposes that PG&amp;E pay $50M for shareholder-funded system enhancements on the company\u2019s electric transmission and distribution system.</li><li>The agreement also proposes that PG&amp;E not seek customer rate recovery associated with certain wildfire costs in the amount of $1.63B.</li><li>PG&amp;E has requested for the CPUC to decide on the settlement by the end of February 2020.</li><li>PG&amp;E shares are <font color=\"green\">up 4%</font> after hours to $11.35.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526976\" data-linked=\"PG&amp;E reaches $1.6B wildfire settlement\" data-tweet=\"$PCG - PG&amp;E reaches $1.6B wildfire settlement https://seekingalpha.com/news/3526976-pg-and-e-reaches-1_6b-wildfire-settlement?source=tweet\" data-url=\"https://seekingalpha.com/news/3526976-pg-and-e-reaches-1_6b-wildfire-settlement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526973\" data-ts=\"1576627251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526973-former-panw-employee-charged-insider-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Former PANW employee charged with insider trading</a></h4><ul><li>The SEC <a href=\"https://www.reuters.com/article/us-usa-sec-insidertrading-palo-alto/u-s-sec-charges-former-palo-alto-networks-it-administrator-others-with-insider-trading-idUSKBN1YL2K5\" target=\"_blank\">charges </a>former Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks, Inc.'>PANW</a>) IT administrator Janardhan Nellore and four friends of insider trading.</li><li>The traders allegedly made over $7M in illegal profits at the height of their scheme in 2017. The activity lasted from 2015 to 2018.</li><li>Palo Alto terminated Nellore's employment earlier this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526973\" data-linked=\"Former PANW employee charged with insider trading\" data-tweet=\"$PANW - Former PANW employee charged with insider trading https://seekingalpha.com/news/3526973-former-panw-employee-charged-insider-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3526973-former-panw-employee-charged-insider-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526966\" data-ts=\"1576621912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526966-fdx-ctas-pacb-and-scs-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDX, CTAS, PACB and SCS among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/ASLN' title='ASLAN Pharmaceuticals Limited'>ASLN</a> <font color=\"green\">+8.6%</font>. <a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a> <font color=\"green\">+7.1%</font>. <a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color=\"green\">+5.5%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a> <font color=\"green\">+2.8%</font>. <a href='https://seekingalpha.com/symbol/CTAS' title='Cintas Corporation'>CTAS</a> <font color=\"green\">+2.8%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/FIXX' title='Homology Medicines, Inc.'>FIXX</a> <font color=\"red\">-17.1%</font>.<strong> </strong><a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California, Inc.'>PACB</a> <font color=\"red\">-9.4%</font>. <a href='https://seekingalpha.com/symbol/NLTX' title='Neoleukin Therapeutics, Inc.'>NLTX</a> <font color=\"red\">-6.7%</font>. <a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a> <font color=\"red\">-6.7%. </font><a href='https://seekingalpha.com/symbol/GTHX' title='G1 Therapeutics, Inc.'>GTHX</a> <font color=\"red\">-4.0%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526966\" data-linked=\"FDX, CTAS, PACB and SCS among after hour movers\" data-tweet=\"$ASLN $NK $SCS - FDX, CTAS, PACB and SCS among after hour movers https://seekingalpha.com/news/3526966-fdx-ctas-pacb-and-scs-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526966-fdx-ctas-pacb-and-scs-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526963\" data-ts=\"1576620451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDSB\" target=\"_blank\">PDSB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526963-pds-bio-down-8-after-hours-on-planned-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PDS Bio down 8% after hours on planned equity offering</a></h4><ul><li>PDS Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/PDSB' title='PDS Biotechnology Corporation'>PDSB</a>) slips <font color=\"red\">8%</font> after hours in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1472091/000114036119022730/nt10006928x1_s1.htm\" target=\"_blank\">planned stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526963\" data-linked=\"PDS Bio down 8% after hours on planned equity offering\" data-tweet=\"$PDSB - PDS Bio down 8% after hours on planned equity offering https://seekingalpha.com/news/3526963-pds-bio-down-8-after-hours-on-planned-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3526963-pds-bio-down-8-after-hours-on-planned-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526949\" data-ts=\"1576618960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPS\" target=\"_blank\">UPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526949-upsminus-2-after-fedex-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UPS -2% after FedEx guidance cut</a></h4><ul><li>Shares of UPS (NYSE:<a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a>) are lower after FedEx misses revenue, EPS and margin expectations with its earnings report. The shipper also slid its full-year guidance lower.</li><li><font color=\"red\">UPS 1.70%</font> AH to $118.25.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526919-fedexminus-4-after-operating-margin-plunge\" target=\"_blank\">FedEx -4% after operating margin plunge</a> (Dec. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526949\" data-linked=\"UPS -2% after FedEx guidance cut\" data-tweet=\"$UPS - UPS -2% after FedEx guidance cut https://seekingalpha.com/news/3526949-upsminus-2-after-fedex-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3526949-upsminus-2-after-fedex-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526937\" data-ts=\"1576617716\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PACB\" target=\"_blank\">PACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526937-pacific-bio-down-8-after-hours-on-u-s-opposition-on-illumina-tie-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Bio down 8% after hours on U.S. opposition on Illumina tie-up</a></h4><ul><li>Pacific Biosciences of California (NASDAQ:<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California, Inc.'>PACB</a>) slips <font color=\"red\">8%</font> after hours in response to reports that U.S. regulators will seek to block its <a href=\"https://seekingalpha.com/news/3404266-illumina-to-acquire-pacific-biosciences-nearminus-100-premium\" target=\"_blank\">$1.2B merger</a> with Illumina (NASDAQ:<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3526937\" data-linked=\"Pacific Bio down 8% after hours on U.S. opposition on Illumina tie-up\" data-tweet=\"$PACB $ILMN - Pacific Bio down 8% after hours on U.S. opposition on Illumina tie-up https://seekingalpha.com/news/3526937-pacific-bio-down-8-after-hours-on-u-s-opposition-on-illumina-tie-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3526937-pacific-bio-down-8-after-hours-on-u-s-opposition-on-illumina-tie-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526926\" data-ts=\"1576617406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIXX\" target=\"_blank\">FIXX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526926-homology-medicines-gene-therapy-shows-encouraging-action-in-pku-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Homology Medicines gene therapy shows encouraging action in PKU study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17730903-homology-medicines-announces-encouraging-initial-clinical-data-from-phenix-gene-therapy-trial\" target=\"_blank\">Preliminary data</a> from a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03952156?spons=homology+medicines&amp;phase=0&amp;draw=2&amp;rank=1\" target=\"_blank\">pheNIX</a>, evaluating Homology Medicines' (NASDAQ:<a href='https://seekingalpha.com/symbol/FIXX' title='Homology Medicines, Inc.'>FIXX</a>) gene therapy HMI-102 in patients with phenylketonuria &#40;PKU&#41; showed encouraging action.</li><li>The first patient dosed experienced a 35% reduction from baseline in phenylalanine at week 1 and 48% at week 4. Tyrosine levels increased 72% and 85%, respectively, at each time point.</li><li>On the safety front, no treatment-emergent adverse events were observed.</li><li>Management will host a conference call today at 4:30 pm ET to discuss the data.</li><li>Shares up <font color=\"green\">1%</font> after hours.</li><li>PKU-related tickers: Synlogic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>), BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>), Codexis (NASDAQ:<a href='https://seekingalpha.com/symbol/CDXS' title='Codexis, Inc.'>CDXS</a>), Rubius Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RUBY' title='Rubius Therapeutics, Inc.'>RUBY</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526926\" data-linked=\"Homology Medicines gene therapy shows encouraging action in PKU study\" data-tweet=\"$FIXX $SYBX $BMRN - Homology Medicines gene therapy shows encouraging action in PKU study https://seekingalpha.com/news/3526926-homology-medicines-gene-therapy-shows-encouraging-action-in-pku-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3526926-homology-medicines-gene-therapy-shows-encouraging-action-in-pku-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526919\" data-ts=\"1576617006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526919-fedexminus-4-after-operating-margin-plunge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx -4% after operating margin plunge</a></h4><ul><li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) reports operating margin fell to 3.2% of sales in <a href=\"https://seekingalpha.com/pr/17730909-fedex-corp-reports-second-quarter-results\" target=\"_blank\">FQ2</a> from 6.6% a year ago due to a variety of factors.</li><li>The shipper points to weak global economic conditions, increased FedEx Ground costs from expanded service offerings, the loss of business from a large customer, a continuing mix shift to lower-yielding services and a more competitive pricing environment. The later Thanksgiving holiday this year was also a drag as it resulted in the shifting of Cyber Week into December.</li><li>Looking ahead, FedEx expects FY20 of EPS $10.25 to $11.50 vs. prior view for $11.00 to $13.00 and $12.09 consensus.</li><li>Shares of FedEx are <font color=\"red\">down 4.40%</font> AH.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526912-fedex-eps-misses-0_27-misses-on-revenue\" target=\"_blank\">FedEx EPS misses by $0.27, misses on revenue</a> (Dec. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526919\" data-linked=\"FedEx -4% after operating margin plunge\" data-tweet=\"$FDX - FedEx -4% after operating margin plunge https://seekingalpha.com/news/3526919-fedexminus-4-after-operating-margin-plunge?source=tweet\" data-url=\"https://seekingalpha.com/news/3526919-fedexminus-4-after-operating-margin-plunge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526918\" data-ts=\"1576616954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCS\" target=\"_blank\">SCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526918-steelcase-eps-beats-0_11-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steelcase EPS beats by $0.11, beats on revenue</a></h4><ul><li>Steelcase (NYSE:<a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a>): Q3 GAAP EPS of $0.46 <font color=\"green\">beats by $0.11</font>.</li><li>Revenue of $955.2M (+6.0% Y/Y) <font color=\"green\">beats by $20.5M</font>.</li><li>Shares <font color=\"green\">+2.83%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17730929-steelcase-reports-third-quarter-fiscal-2020-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526918\" data-linked=\"Steelcase EPS beats by $0.11, beats on revenue\" data-tweet=\"$SCS - Steelcase EPS beats by $0.11, beats on revenue https://seekingalpha.com/news/3526918-steelcase-eps-beats-0_11-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3526918-steelcase-eps-beats-0_11-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526909\" data-ts=\"1576616397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCNNF\" target=\"_blank\">TCNNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526909-trulieve-defended-stifel-sharesminus-14-close\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trulieve defended by Stifel; shares -14% into the close</a></h4><ul><li>The short report mostly focuses on the questionable business practices of the Trulieve (<a href='https://seekingalpha.com/symbol/TCNNF' title='Trulieve Cannabis Corp.'>OTCPK:TCNNF</a>) CEO's husband, rather the company's operations, <a href=\"https://mobile.twitter.com/BettingBruiser/status/1206977934671667200\" target=\"_blank\">says analyst Robert Fagan</a>.</li><li>That the company's insiders were involved in FBI probes isn't new news, says Fagan. Nor is it new that CEO Rivers' husband was the company's main construction partner.</li><li>Further, it's irrelevant that most of the company's 1.7M cultivation footprint produces low-quality output. The company has been clear about its use of experimental greenhouses which produce lower yields, and most of the output is for extract production, which does not require high-quality flower.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526901-trulieve-responds-to-fraud-report-shares-slide\" target=\"_blank\">Trulieve responds to fraud report as shares slide</a> (Dec. 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526796-fraud-allegations-against-trulieve\" target=\"_blank\">Fraud allegations against Trulieve</a> (Dec. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526909\" data-linked=\"Trulieve defended by Stifel; shares -14% into the close\" data-tweet=\"$TCNNF - Trulieve defended by Stifel; shares -14% into the close https://seekingalpha.com/news/3526909-trulieve-defended-stifel-sharesminus-14-close?source=tweet\" data-url=\"https://seekingalpha.com/news/3526909-trulieve-defended-stifel-sharesminus-14-close\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526908\" data-ts=\"1576616360\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TUP\" target=\"_blank\">TUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526908-volatility-on-tupperware-jets-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volatility on Tupperware jets higher</a></h4><ul><li>Tupperware Brands (<a href='https://seekingalpha.com/symbol/TUP' title='Tupperware Brands Corporation'>TUP</a> <font color='green'>+9.2%</font>) pops with elevated volatility on a day that call option volume is being reported at 40X normal activity.</li><li>No corporate news is out from Tupperware today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526908\" data-linked=\"Volatility on Tupperware jets higher\" data-tweet=\"$TUP - Volatility on Tupperware jets higher https://seekingalpha.com/news/3526908-volatility-on-tupperware-jets-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3526908-volatility-on-tupperware-jets-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526903\" data-ts=\"1576614884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSG\" target=\"_blank\">MSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526903-madison-square-garden-gains-after-jefferies-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Madison Square Garden gains after Jefferies nod</a></h4><ul> <li>Jefferies starts off coverage on Madison Square Garden (<a href='https://seekingalpha.com/symbol/MSG' title='The Madison Square Garden Company'>MSG</a> <font color='green'>+1.4%</font>) with a Buy rating due to a positive view of the media company's growth profile.</li><li>\"In our view, the prospective spin highlights the previously obscure asset value, growth potential, and sports betting optionality of both entities. SportsCo\u2019s stability and future optionality become clearer, as do EntertainmentCo's real estate value and events growth, despite near-term volatility on competition and Sphere discourse,\" advises the firm.</li><li>The MSG sports assets by themselves are estimated to be worth $182 per share.</li> <li>The firm comes up with a sum-of-the-parts price target of $370 vs. the average sell-side price target of $343.27.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3526903\" data-linked=\"Madison Square Garden gains after Jefferies nod\" data-tweet=\"$MSG - Madison Square Garden gains after Jefferies nod https://seekingalpha.com/news/3526903-madison-square-garden-gains-after-jefferies-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3526903-madison-square-garden-gains-after-jefferies-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526901\" data-ts=\"1576614530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCNNF\" target=\"_blank\">TCNNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526901-trulieve-responds-to-fraud-report-shares-slide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trulieve responds to fraud report as shares slide</a></h4><ul><li>\"The quality of Trulieve\u2019s (<a href='https://seekingalpha.com/symbol/TCNNF' title='Trulieve Cannabis Corp.'>OTCPK:TCNNF</a> <font color='red'>-15.1%</font>) products and production facilities has never been in question,\" <a href=\"https://seekingalpha.com/pr/17730756-trulieve-responds-to-short-seller-report\" target=\"_blank\">says the company</a>, responding to <a href=\"https://seekingalpha.com/news/3526796-fraud-allegations-against-trulieve\" target=\"_blank\">fraud accusations earlier today</a> from Grizzly Research.</li><li>The company plans to pursue legal action against Grizzly.</li><li>CEO Kim Rivers: \"I have full confidence in our management team and their abilities to continue to serve our customers without being distracted by these baseless allegations.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3526901\" data-linked=\"Trulieve responds to fraud report as shares slide\" data-tweet=\"$TCNNF - Trulieve responds to fraud report as shares slide https://seekingalpha.com/news/3526901-trulieve-responds-to-fraud-report-shares-slide?source=tweet\" data-url=\"https://seekingalpha.com/news/3526901-trulieve-responds-to-fraud-report-shares-slide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526900\" data-ts=\"1576614250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXCM\" target=\"_blank\">DXCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526900-data-sharing-snafu-due-to-cloud-provider-switch-dexcom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Data-sharing snafu due to cloud provider switch - DexCom</a></h4><ul><li>DexCom (<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color=\"green\">+2.4%</font>) says the <a href=\"https://seekingalpha.com/news/3522944-dexcom-down-2-on-g6-app-glitches\" target=\"_blank\">recent failure</a> of its G6 remote monitoring feature was related to its <a href=\"https://www.wsj.com/articles/diabetes-blood-sugar-data-outage-blamed-on-cloud-provider-switch-11576611635?mod=pls_whats_news_us_business_f\" target=\"_blank\">change </a>of cloud-computing service providers.</li><li>According to CEO Kevin Sayer, the company switched to a new vendor for its data-sharing feature, but then DexCom introduced new platform components that \"weren't configured for optimal performance.\" Core processes within the platform were disrupted when these components failed.</li><li>The company is reviewing its computer systems and making changes to ensure that such a snafu does not recur.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526900\" data-linked=\"Data-sharing snafu due to cloud provider switch - DexCom\" data-tweet=\"$DXCM - Data-sharing snafu due to cloud provider switch - DexCom https://seekingalpha.com/news/3526900-data-sharing-snafu-due-to-cloud-provider-switch-dexcom?source=tweet\" data-url=\"https://seekingalpha.com/news/3526900-data-sharing-snafu-due-to-cloud-provider-switch-dexcom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526891\" data-ts=\"1576613086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526891-verb-technology-and-brooks-automation-among-tech-gainers-groupon-and-uxin-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verb Technology and Brooks Automation among Tech gainers; Groupon and Uxin among losers</a></h4><ul><li><b>Gainers: </b>Verb Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/VERB' title='Verb Technology Company, Inc.'>VERB</a>) <font color=\"green\">+13%</font>. Brooks Automation (NASDAQ:<a href='https://seekingalpha.com/symbol/BRKS' title='Brooks Automation, Inc.'>BRKS</a>) <font color=\"green\">+8%</font>. Qudian (NYSE:<a href='https://seekingalpha.com/symbol/QD' title='Qudian Inc.'>QD</a>) <font color=\"green\">+8%</font>. Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) <font color=\"green\">+7%</font>. Luokung Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/LKCO' title='Luokung Technology Corp.'>LKCO</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) <font color=\"red\">-10%</font>. Uxin (NASDAQ:<a href='https://seekingalpha.com/symbol/UXIN' title='Uxin Limited'>UXIN</a>) <font color=\"red\">-9%</font>. Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"red\">-8%</font>. YayYo (NASDAQ:<a href='https://seekingalpha.com/symbol/YAYO' title='YayYo, Inc.'>YAYO</a>) <font color=\"red\">-7%</font>. Domo (NASDAQ:<a href='https://seekingalpha.com/symbol/DOMO' title='Domo, Inc.'>DOMO</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526891\" data-linked=\"Verb Technology and Brooks Automation among Tech gainers; Groupon and Uxin among losers\" data-tweet=\"$VERB $BRKS $QD - Verb Technology and Brooks Automation among Tech gainers; Groupon and Uxin among losers https://seekingalpha.com/news/3526891-verb-technology-and-brooks-automation-among-tech-gainers-groupon-and-uxin-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526891-verb-technology-and-brooks-automation-among-tech-gainers-groupon-and-uxin-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526886\" data-ts=\"1576611456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526886-cnbc-survey-shows-microsoft-teams-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC survey shows Microsoft Teams strength</a></h4><ul><li>The Q4 CNBC Technology Executive Council Survey <a href=\"https://www.cnbc.com/2019/12/17/microsoft-teams-more-popular-than-slack-at-big-firms-cnbc-survey.html\" target=\"_blank\">is out</a>, and 58% of respondents say they use Microsoft (<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> <font color='red'>-0.6%</font>) Teams versus the 30% who use Slack (<a href='https://seekingalpha.com/symbol/WORK' title='Slack Technologies, Inc.'>WORK</a> <font color='red'>-2.2%</font>).</li><li>The survey includes a limited sampling of 51 of the 157 members of the council, who serve in senior tech positions at large enterprises, government organizations, and nonprofits.</li><li>Last month, Microsoft announced that Teams had more than 20M DAUs. Slack had reported 12M in October.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526886\" data-linked=\"CNBC survey shows Microsoft Teams strength\" data-tweet=\"$MSFT $WORK - CNBC survey shows Microsoft Teams strength https://seekingalpha.com/news/3526886-cnbc-survey-shows-microsoft-teams-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3526886-cnbc-survey-shows-microsoft-teams-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526884\" data-ts=\"1576609515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526884-renewable-energy-and-tallgrass-energy-among-energy-materials-gainers-lonestar-resources-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Renewable Energy and Tallgrass Energy among Energy/Materials gainers; Lonestar Resources and Pacific Drilling among losers</a></h4><ul><li><b>Gainers: </b>Renewable Energy Group (NASDAQ:<a href='https://seekingalpha.com/symbol/REGI' title='Renewable Energy Group, Inc.'>REGI</a>) <font color=\"green\">+31%</font>. Tallgrass Energy (NYSE:<a href='https://seekingalpha.com/symbol/TGE' title='Tallgrass Energy, LP'>TGE</a>) <font color=\"green\">+21%</font>. HighPoint Resources (NYSE:<a href='https://seekingalpha.com/symbol/HPR' title='HighPoint Resources Corporation'>HPR</a>) <font color=\"green\">+15%</font>. Contango Oil &amp; Gas (NYSEMKT:<a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a>) <font color=\"green\">+13%</font>. LSB Industries (NYSE:<a href='https://seekingalpha.com/symbol/LXU' title='LSB Industries, Inc.'>LXU</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers: </b>Lonestar Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/LONE' title='Lonestar Resources US Inc.'>LONE</a>) <font color=\"red\">-6%</font>. Pacific Drilling (NYSE:<a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling S.A.'>PACD</a>) <font color=\"red\">-6%</font>. Loop Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LOOP' title='Loop Industries, Inc.'>LOOP</a>) <font color=\"red\">-5%</font>. Frank's International (NYSE:<a href='https://seekingalpha.com/symbol/FI' title='Frank&#39;s International N.V.'>FI</a>) <font color=\"red\">-5%</font>. Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526884\" data-linked=\"Renewable Energy and Tallgrass Energy among Energy/Materials gainers; Lonestar Resources and Pacific Drilling among losers\" data-tweet=\"$REGI $TGE $HPR - Renewable Energy and Tallgrass Energy among Energy/Materials gainers; Lonestar Resources and Pacific Drilling among losers https://seekingalpha.com/news/3526884-renewable-energy-and-tallgrass-energy-among-energy-materials-gainers-lonestar-resources-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3526884-renewable-energy-and-tallgrass-energy-among-energy-materials-gainers-lonestar-resources-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526878\" data-ts=\"1576607399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHV\" target=\"_blank\">ACHV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526878-achieve-life-sciences-down-34-after-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achieve Life Sciences down 34% after pricing equity offering</a></h4><ul><li>Achieve Life Sciences (<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color=\"red\">-34.1%</font>) is down on a robust 90x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/17730737-achieve-life-sciences-announces-pricing-of-12-million-underwritten-public-offering\" target=\"_blank\">$12M public offering</a> of Class A &amp; B units.</li><li>Class A units, each consisting of one common share and one five-year warrant exercisable at $0.60 per share, are priced at $0.60.</li><li>Class B units, consisting of one share of Series B preferred stock, convertible into 1,666 common shares and one five-year warrant to purchase 1,666 common shares at $0.60 per share, are priced at $999.60.</li><li>A total of 9,577,504 common shares, 6,256 shares of Series B preferred stock convertible into an aggregate of 10,422,496 common shares and total warrants to purchase 20,000,000 common shares will be issued in the offering.</li><li>Closing date is December 19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526878\" data-linked=\"Achieve Life Sciences down 34% after pricing equity offering\" data-tweet=\"$ACHV - Achieve Life Sciences down 34% after pricing equity offering https://seekingalpha.com/news/3526878-achieve-life-sciences-down-34-after-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3526878-achieve-life-sciences-down-34-after-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526876\" data-ts=\"1576606615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOGM\" target=\"_blank\">LOGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526876-berenberg-expects-higher-offer-for-logmein\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Berenberg expects higher offer for LogMeIn</a></h4><ul><li>Berenberg analyst Brett Knoblauch says the LogMeIn (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGM' title='LogMeIn, Inc.'>LOGM</a>) <a href=\"https://seekingalpha.com/news/3526786-logmein-acquired-for-86_05-per-share\" target=\"_blank\">acquisition offer</a> from Francisco Partners and Elliott\u2019s Evergreen Coast for $86.05 appears a low bid.</li><li>The analyst says LOGM could see a higher offer during its go-shop period. Berenberg previously had a $91 target on LogMeIn.</li><li>The firm now cuts LOGM from Buy to Hold and the target to the announced deal price.</li><li>LogMeIn shares are <font color=\"green\">up 4.1%</font> to $85.78.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526876\" data-linked=\"Berenberg expects higher offer for LogMeIn\" data-tweet=\"$LOGM - Berenberg expects higher offer for LogMeIn https://seekingalpha.com/news/3526876-berenberg-expects-higher-offer-for-logmein?source=tweet\" data-url=\"https://seekingalpha.com/news/3526876-berenberg-expects-higher-offer-for-logmein\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526875\" data-ts=\"1576606386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHR\" target=\"_blank\">WHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526875-whirlpoolminus-2-after-large-recall-in-u-k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whirlpool -2% after large recall in U.K.</a></h4><ul> <li>Whirlpool (<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a> <font color='red'>-1.7%</font>) <a href=\"https://www.bbc.com/news/business-50811686\" target=\"_blank\">recalls</a> up to 519K washing machines in the U.K. due to the risk of a fire from overheating.</li> <li>Around 20% of all Hotpoint and Indesit washing machines made by Whirlpool are part of the recall action.</li> <li>The issue is separate from a faulty dryer problem in the U.K., also related to a fire risk.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3526875\" data-linked=\"Whirlpool -2% after large recall in U.K.\" data-tweet=\"$WHR - Whirlpool -2% after large recall in U.K. https://seekingalpha.com/news/3526875-whirlpoolminus-2-after-large-recall-in-u-k?source=tweet\" data-url=\"https://seekingalpha.com/news/3526875-whirlpoolminus-2-after-large-recall-in-u-k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526873\" data-ts=\"1576605903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526873-firsthand-technology-value-fund-and-itau-corpbanca-among-financial-gainers-mmtec-and-jupai\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Firsthand Technology Value Fund and Itau CorpBanca among Financial gainers; Mmtec and Jupai among losers</a></h4><ul><li><b>Gainers: </b>Firsthand Technology Value Fund (NASDAQ:<a href='https://seekingalpha.com/symbol/SVVC' title='Firsthand Technology Value Fund'>SVVC</a>) <font color=\"green\">+10%</font>. Itau CorpBanca (NYSE:<a href='https://seekingalpha.com/symbol/ITCB' title='Itaú CorpBanca'>ITCB</a>) <font color=\"green\">+6%</font>. BRP Group (NASDAQ:<a href='https://seekingalpha.com/symbol/BRP' title='BRP Group, Inc.'>BRP</a>) <font color=\"green\">+6%</font>. Elevate Credit (NYSE:<a href='https://seekingalpha.com/symbol/ELVT' title='Elevate Credit, Inc.'>ELVT</a>) <font color=\"green\">+5%</font>. Manning &amp; Napier (NYSE:<a href='https://seekingalpha.com/symbol/MN' title='Manning & Napier, Inc.'>MN</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Mmtec (NASDAQ:<a href='https://seekingalpha.com/symbol/MTC' title='Mmtec, Inc.'>MTC</a>) <font color=\"red\">-10%</font>. Jupai (NYSE:<a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings Limited'>JP</a>) <font color=\"red\">-8%</font>. Carver Bancorp (NASDAQ:<a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a>) <font color=\"red\">-7%</font>. Lloyds Banking Group (NYSE:<a href='https://seekingalpha.com/symbol/LYG' title='Lloyds Banking Group plc'>LYG</a>) <font color=\"red\">-7%</font>. Cohen (NYSEMKT:<a href='https://seekingalpha.com/symbol/COHN' title='Cohen & Company Inc.'>COHN</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526873\" data-linked=\"Firsthand Technology Value Fund and Itau CorpBanca among Financial gainers; Mmtec and Jupai among losers\" data-tweet=\"$SVVC $ITCB $BRP - Firsthand Technology Value Fund and Itau CorpBanca among Financial gainers; Mmtec and Jupai among losers https://seekingalpha.com/news/3526873-firsthand-technology-value-fund-and-itau-corpbanca-among-financial-gainers-mmtec-and-jupai?source=tweet\" data-url=\"https://seekingalpha.com/news/3526873-firsthand-technology-value-fund-and-itau-corpbanca-among-financial-gainers-mmtec-and-jupai\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526869\" data-ts=\"1576605595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526869-darling-ingredients-and-vertex-energy-among-industrial-gainers-dmc-global-tops-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Darling Ingredients and Vertex Energy among industrial gainers; DMC Global tops losers</a></h4><ul><li><b>Gainers: </b>Perma-Fix Environmental Services (NASDAQ:<a href='https://seekingalpha.com/symbol/PESI' title='Perma-Fix Environmental Services, Inc.'>PESI</a>) <font color=\"green\">+9%</font>. Omega Flex (NASDAQ:<a href='https://seekingalpha.com/symbol/OFLX' title='Omega Flex, Inc.'>OFLX</a>) <font color=\"green\">+7%</font>. Astec Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/ASTE' title='Astec Industries, Inc.'>ASTE</a>) <font color=\"green\">+7%</font>. Vertex Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/VTNR' title='Vertex Energy, Inc.'>VTNR</a>) <font color=\"green\">+7%</font>. Darling Ingredients (NYSE:<a href='https://seekingalpha.com/symbol/DAR' title='Darling Ingredients Inc.'>DAR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>DMC Global (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOM' title='DMC Global Inc.'>BOOM</a>) <font color=\"red\">-17%</font>. U.S. Well Services (NASDAQ:<a href='https://seekingalpha.com/symbol/USWS' title='U.S. Well Services, Inc.'>USWS</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526869\" data-linked=\"Darling Ingredients and Vertex Energy among industrial gainers; DMC Global tops losers\" data-tweet=\"$PESI $OFLX $ASTE - Darling Ingredients and Vertex Energy among industrial gainers; DMC Global tops losers https://seekingalpha.com/news/3526869-darling-ingredients-and-vertex-energy-among-industrial-gainers-dmc-global-tops-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526869-darling-ingredients-and-vertex-energy-among-industrial-gainers-dmc-global-tops-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526867\" data-ts=\"1576604791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVH\" target=\"_blank\">EVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526867-evolent-down-6-on-loss-of-key-contract-in-ny\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evolent down 6% on loss of key contract in NY</a></h4><ul><li>Evolent Health (<a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health, Inc.'>EVH</a> <font color=\"red\">-5.6%</font>) is down on over 50% higher volume. Shares have struggled since plunging <font color=\"red\">27%</font> on November 27 over uncertainty with acquisition target Passport Health's participation in Kentucky's Medicaid contract which has historically accounted for almost all of its revenue. The new governor is currently assessing the situation, precipitated by a decision by the outgoing administration to <a href=\"https://seekingalpha.com/news/3522421-evolent-health-plunges-after-kentucky-medicaid-contract-news\" target=\"_blank\">award the contract</a> to other providers.</li><li>In a note today, Goldman Sachs reported that Evolent has lost a contract with a 2,500 member-strong physician group in New York, <a href=\"https://somoscommunitycare.org/\" target=\"_blank\">SOMOS</a>, that was a key client since 2018.</li><li><strong>Update</strong>: SunTrust notes that Evolent's overall relationship with SOMOS is actually expanding. The particular contract that is ending is related to the Delivery System Incentive Program which was known and already factored into guidance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526867\" data-linked=\"Evolent down 6% on loss of key contract in NY\" data-tweet=\"$EVH - Evolent down 6% on loss of key contract in NY https://seekingalpha.com/news/3526867-evolent-down-6-on-loss-of-key-contract-in-ny?source=tweet\" data-url=\"https://seekingalpha.com/news/3526867-evolent-down-6-on-loss-of-key-contract-in-ny\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526866\" data-ts=\"1576604517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526866-clne-trxc-tge-and-adms-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CLNE, TRXC, TGE and ADMS among midday movers</a></h4><ul><li><strong>Gainers: </strong>Kaixin Auto (NASDAQ:<a href='https://seekingalpha.com/symbol/KXIN' title='Kaixin Auto Holdings'>KXIN</a>) <font color=\"green\">+32%</font>.</li><li>NantKwest (NASDAQ:<a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a>) <font color=\"green\">+31%</font>.</li><li>Renewable Energy Group (NASDAQ:<a href='https://seekingalpha.com/symbol/REGI' title='Renewable Energy Group, Inc.'>REGI</a>) <font color=\"green\">+29%</font>.</li><li>Venus Concept (NASDAQ:<a href='https://seekingalpha.com/symbol/VERO' title='Venus Concept Inc.'>VERO</a>) <font color=\"green\">+22%</font>.</li><li>TravelCenters of America (NASDAQ:<a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America Inc.'>TA</a>) <font color=\"green\">+21%</font>.</li><li>Tallgrass Energy (NYSE:<a href='https://seekingalpha.com/symbol/TGE' title='Tallgrass Energy, LP'>TGE</a>) <font color=\"green\">+21%</font>.</li><li>Precipio (NASDAQ:<a href='https://seekingalpha.com/symbol/PRPO' title='Precipio, Inc.'>PRPO</a>) <font color=\"green\">+20%</font>.</li><li>Oncolytics Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCY' title='Oncolytics Biotech Inc.'>ONCY</a>) <font color=\"green\">+20%</font>.</li><li>Clean Energy Fuels (NASDAQ:<a href='https://seekingalpha.com/symbol/CLNE' title='Clean Energy Fuels Corp.'>CLNE</a>) <font color=\"green\">+19%</font>.</li><li>Acasti Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma Inc.'>ACST</a>) <font color=\"green\">+14%</font>.</li><li><strong>Losers: </strong>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"red\">-57%</font>.</li><li>Adamas Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a>) <font color=\"red\">-42%</font>.</li><li>MEI Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/MEIP' title='MEI Pharma, Inc.'>MEIP</a>) <font color=\"red\">-26%</font>.</li><li>DMC Global (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOM' title='DMC Global Inc.'>BOOM</a>) <font color=\"red\">-17%</font>.</li><li>LMP Automotive (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"red\">-15%</font>.</li><li>VistaGen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a>) <font color=\"red\">-13%</font>.</li><li>Adial Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADIL' title='Adial Pharmaceuticals, Inc.'>ADIL</a>) <font color=\"red\">-13%</font>.</li><li>TransEnterix (NYSEMKT:<a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a>) <font color=\"red\">-12%</font>.</li><li>electroCore (NASDAQ:<a href='https://seekingalpha.com/symbol/ECOR' title='electroCore, Inc.'>ECOR</a>) <font color=\"red\">-13%</font>.</li><li>CohBar (NASDAQ:<a href='https://seekingalpha.com/symbol/CWBR' title='CohBar, Inc.'>CWBR</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526866\" data-linked=\"CLNE, TRXC, TGE and ADMS among midday movers\" data-tweet=\"$KXIN $NK $REGI - CLNE, TRXC, TGE and ADMS among midday movers https://seekingalpha.com/news/3526866-clne-trxc-tge-and-adms-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526866-clne-trxc-tge-and-adms-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526856\" data-ts=\"1576602454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526856-tupperware-brands-among-consumer-gainers-unilever-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tupperware Brands among consumer gainers; Unilever leads the losers</a></h4><ul><li><b>Gainers: </b>Vince Holding (NYSE:<a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a>) <font color=\"green\">+11%</font>. Pingtan Marine Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a>) <font color=\"green\">+9%</font>. Tupperware Brands (NYSE:<a href='https://seekingalpha.com/symbol/TUP' title='Tupperware Brands Corporation'>TUP</a>) <font color=\"green\">+9%</font>.  The Lovesac (NASDAQ:<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a>) <font color=\"green\">+8%</font>. The Alkaline Water (NASDAQ:<a href='https://seekingalpha.com/symbol/WTER' title='The Alkaline Water Company Inc.'>WTER</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>The Unilever (NYSE:<a href='https://seekingalpha.com/symbol/UL' title='The Unilever Group'>UL</a>) <font color=\"red\">-9%</font>. Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"red\">-9%</font>. Navistar International (NYSE:<a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a>) <font color=\"red\">-8%</font>. Calyxt (NASDAQ:<a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a>) <font color=\"red\">-8%</font>. Vuzix (NASDAQ:<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corporation'>VUZI</a>) <font color=\"red\">-7</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526856\" data-linked=\"Tupperware Brands among consumer gainers; Unilever leads the losers\" data-tweet=\"$VNCE $PME $TUP - Tupperware Brands among consumer gainers; Unilever leads the losers https://seekingalpha.com/news/3526856-tupperware-brands-among-consumer-gainers-unilever-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526856-tupperware-brands-among-consumer-gainers-unilever-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526850\" data-ts=\"1576600581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMS\" target=\"_blank\">ADMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526850-adamas-pharma-plunges-after-mixed-results-in-ms-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamas Pharma plunges after mixed results in MS trial</a></h4><ul><li>\"As we did not see the scale of clinical benefit we had hoped for in this study <a href=\"https://seekingalpha.com/pr/17730325-adamas-announces-top-line-results-from-inroads-phase-3-trial-of-adsminus-5102-for-multiple\" target=\"_blank\">we will fully assess the potential </a>for ADS-5102 in MS patients before determining the extent of our continued investment in this program,\" says Adamas (<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color=\"red\">-40.7%</font>) CEO Neil McFarlane after mixed results in the drug's Phase 3 trial.</li><li>The 274 mg dose showed improvement in the timed 25-foot walk after 12 weeks, but the lower did not, and neither dose showed a significant effect on secondary walking measures.</li><li>Already bearish on the name, BAML cuts its price target to $3. \"Visibility needed on path forward in MSWI,\" says the team.</li><li>Evercore, meanwhile, <a href=\"https://twitter.com/thenotablecalls/status/1206964818923667456\" target=\"_blank\">is launching a spirited defense</a> of its $45 price target. Analyst Joel Schimmer says this marks the final of many mistakes from prior management. \"The new team can execute on Gocovri for LID with a clean slate and lightly explore other pipeline opportunities.\"</li><li>Shares are currently trading hands at $4.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526850\" data-linked=\"Adamas Pharma plunges after mixed results in MS trial\" data-tweet=\"$ADMS - Adamas Pharma plunges after mixed results in MS trial https://seekingalpha.com/news/3526850-adamas-pharma-plunges-after-mixed-results-in-ms-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3526850-adamas-pharma-plunges-after-mixed-results-in-ms-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526828\" data-ts=\"1576599396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVS\" target=\"_blank\">CVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526828-cvs-and-walgreens-in-red-on-ny-lawsuit-over-billing-practices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CVS and Walgreens in red on NY lawsuit over billing practices</a></h4><ul><li>CVS Health (<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a> <font color=\"red\">-0.8%</font>) and Walgreens Boots Alliance (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a> <font color=\"red\">-1.3%</font>) are both near session lows in apparent response to reports that pharmacy benefit provider &#40;PBM&#41; CVS Omnicare has been sued in New York over alleged fraudulent billing practices.</li><li>In May 2017, Omnicare paid $8M to <a href=\"https://www.reuters.com/article/us-cvs-health-lawsuit-idUSKCN18C2LK\" target=\"_blank\">settle </a>a whistleblower-instigated lawsuit filed by the federal government and 28 states over charges that its prescription verification system generated false claims submitted to government healthcare programs, specifically, claims for more profitable generic drugs than those dispensed to patients.</li><li>PBM-related tickers: Humana (<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color=\"red\">-0.8%</font>), UnitedHealth Group (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Incorporated'>UNH</a> <font color=\"red\">-0.4%</font>), Magellan Health (<a href='https://seekingalpha.com/symbol/MGLN' title='Magellan Health, Inc.'>MGLN</a> <font color=\"red\">-1.3%</font>), Cigna (<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color=\"red\">-1%</font>), Anthem (<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color=\"red\">-0.3%</font>), Centene (<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color=\"red\">-1.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526828\" data-linked=\"CVS and Walgreens in red on NY lawsuit over billing practices\" data-tweet=\"$CVS $WBA $HUM - CVS and Walgreens in red on NY lawsuit over billing practices https://seekingalpha.com/news/3526828-cvs-and-walgreens-in-red-on-ny-lawsuit-over-billing-practices?source=tweet\" data-url=\"https://seekingalpha.com/news/3526828-cvs-and-walgreens-in-red-on-ny-lawsuit-over-billing-practices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526839\" data-ts=\"1576599045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SO\" target=\"_blank\">SO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526839-southern-gains-2_9-on-georgia-rate-case-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southern gains 2.9% on Georgia rate case approval</a></h4><ul><li>Southern Co. (NYSE:<a href='https://seekingalpha.com/symbol/SO' title='The Southern Company'>SO</a>)<font color=\"green\"> advances 2.9%</font> after the Georgia Public Service Commission approves SO's Georgia Power rate case.</li><li>Decision allows for a 10.5%-12% return on equity and a capital structure of 56% equity and 44% debt, a spokesman for the commission told Bloomberg News.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526524-southern-co-rises-1_5-bofa-sees-constructive-outcome-of-rate-case\" target=\"_blank\">Southern Co. rises 1.5% as BofA sees 'constructive outcome' of rate case</a> (Dec. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526839\" data-linked=\"Southern gains 2.9% on Georgia rate case approval\" data-tweet=\"$SO - Southern gains 2.9% on Georgia rate case approval https://seekingalpha.com/news/3526839-southern-gains-2_9-on-georgia-rate-case-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3526839-southern-gains-2_9-on-georgia-rate-case-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526827\" data-ts=\"1576598625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JO\" target=\"_blank\">JO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526827-brazil-coffee-production-falls-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil coffee production falls 20%</a></h4><ul> <li>Brazil farm statistics agency Conab estimates farmers in the nation harvested <a href=\"https://www.conab.gov.br/\" target=\"_blank\">49.31M</a> bags this year vs. a prior forecast of 48.99M bags.</li> <li>Conab says 15.01M bags of robusta coffee beans was produced vs. 14.52M prior forecast and 34.30M bags of arabica vs. 34.47M prior forecast.</li> <li>Overall, coffee production fell about 20% for the year in comparison to 2018 due partially to weather and insect issues.</li> <li>Coffee prices are <font color=\"red\">down 2.07%</font> to $1.33 per pound to cut into yesterday's sharp rally.</li> <li>Related ETF: iPath Series B Bloomberg Coffee Subindex Total Return ETN (NYSEARCA:<a href='https://seekingalpha.com/symbol/JO' title='iPath Series B Bloomberg Coffee Subindex Total Return ETN'>JO</a>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526633-panic-in-coffee-markets\" target=\"_blank\">Panic in the coffee markets</a> (Dec. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526827\" data-linked=\"Brazil coffee production falls 20%\" data-tweet=\"$JO - Brazil coffee production falls 20% https://seekingalpha.com/news/3526827-brazil-coffee-production-falls-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3526827-brazil-coffee-production-falls-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526825\" data-ts=\"1576598518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526825-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Precipio (NASDAQ:<a href='https://seekingalpha.com/symbol/PRPO' title='Precipio, Inc.'>PRPO</a>) <font color=\"green\">+44%</font>. NantKwest (NASDAQ:<a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a>) <font color=\"green\">+20%</font>. Oncolytics Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCY' title='Oncolytics Biotech Inc.'>ONCY</a>) <font color=\"green\">+19%</font>. Venus Concept (NASDAQ:<a href='https://seekingalpha.com/symbol/VERO' title='Venus Concept Inc.'>VERO</a>) <font color=\"green\">+17%</font>. ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"red\">-57%</font>. Adamas Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a>) <font color=\"red\">-44%</font>. MEI Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/MEIP' title='MEI Pharma, Inc.'>MEIP</a>) <font color=\"red\">-26%</font>. Adial Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADIL' title='Adial Pharmaceuticals, Inc.'>ADIL</a>) <font color=\"red\">-17%</font>. NanoViricides (NYSEMKT:<a href='https://seekingalpha.com/symbol/NNVC' title='NanoViricides, Inc.'>NNVC</a>) <font color=\"red\">-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526825\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$PRPO $NK $ONCY - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3526825-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526825-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526816\" data-ts=\"1576597367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCPL\" target=\"_blank\">SCPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526816-sciplayminus-7_6-after-two-notch-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SciPlay -7.6% after two-notch downgrade</a></h4><ul><li>Goldman Sachs cuts SciPlay (NASDAQ:<a href='https://seekingalpha.com/symbol/SCPL' title='SciPlay Corporation'>SCPL</a>) from Buy to Sell and trims the target by $2 to $10.</li><li>Analyst Michael Ng thinks the company's move towards emerging casual games may prove more difficult than expected.</li><li>Ng also notes the \"stagnant bookings\" for a number of SCPL's games, which reduces his confidence that the titles can scale \"toward Jackpot Party\u2019s higher levels of monetization.\"</li><li>SciPlay shares are <font color=\"red\">down 7.6%</font> to $11.82.</li><li>SCPL has a Bullish average <a href=\"https://seekingalpha.com/symbol/SCPL/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a> with 9 Buy-equivalent ratings out of the 11 total.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526816\" data-linked=\"SciPlay -7.6% after two-notch downgrade\" data-tweet=\"$SCPL - SciPlay -7.6% after two-notch downgrade https://seekingalpha.com/news/3526816-sciplayminus-7_6-after-two-notch-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3526816-sciplayminus-7_6-after-two-notch-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526814\" data-ts=\"1576596850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XXII\" target=\"_blank\">XXII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526814-22nd-century-pops-after-fda-win\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">22nd Century pops after FDA win</a></h4><ul> <li>22nd Century Group (<a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color=\"green\">+24.8%</font>) moves higher after the FDA approved two new reduced nicotine cigarettes through the premarket tobacco product application pathway.</li> <li>Combusted, filtered cigarette brands Moonlight and Moonlight Menthol landed the approvals. Both contain a reduced amount of nicotine compared to typical commercial cigarettes.</li> <li><a href=\"https://www.fda.gov/news-events/press-announcements/fda-permits-sale-two-new-reduced-nicotine-cigarettes-through-premarket-tobacco-product-application\" target=\"_blank\">FDA press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3526814\" data-linked=\"22nd Century pops after FDA win\" data-tweet=\"$XXII - 22nd Century pops after FDA win https://seekingalpha.com/news/3526814-22nd-century-pops-after-fda-win?source=tweet\" data-url=\"https://seekingalpha.com/news/3526814-22nd-century-pops-after-fda-win\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526812\" data-ts=\"1576596562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526812-investors-eye-unilever-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors eye Unilever warning</a></h4><ul> <li>A sales warning from Unilever (<a href='https://seekingalpha.com/symbol/UN' title='The Unilever Group'>UN</a>, <a href='https://seekingalpha.com/symbol/UL' title='The Unilever Group'>UL</a>) is impacting trading in other personal care product companies.</li> <li>Unilever warned about weakness in South Asia and North America in particular.</li> <li>While Unilever is <font color=\"red\">down 7.25%</font> in London trading, the list of slightly underperforming peers includes Colgate-Palmolive (<a href='https://seekingalpha.com/symbol/CL' title='Colgate-Palmolive Company'>CL</a> <font color='red'>-0.9%</font>), Kimberly-Clark (<a href='https://seekingalpha.com/symbol/KMB' title='Kimberly-Clark Corporation'>KMB</a> <font color='red'>-0.1%</font>), Procter &amp; Gamble (<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a> <font color='red'>-0.6%</font>), Nestle (<a href='https://seekingalpha.com/symbol/NSRGY' title='Nestlé S.A.'>OTCPK:NSRGY</a> <font color='red'>-0.8%</font>), Estee Lauder (<a href='https://seekingalpha.com/symbol/EL' title='The Estée Lauder Companies Inc.'>EL</a> <font color='red'>-1.3%</font>) and Revlon (<a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='red'>-2%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526673-unilever-sales-growth-will-miss-forecasts\" target=\"_blank\">Unilever sales growth will miss forecasts</a> (Dec. 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526812\" data-linked=\"Investors eye Unilever warning\" data-tweet=\"$UN $UL $CL - Investors eye Unilever warning https://seekingalpha.com/news/3526812-investors-eye-unilever-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3526812-investors-eye-unilever-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526811\" data-ts=\"1576596528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMHLY\" target=\"_blank\">NMHLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526811-nmc-health-down-39-on-bearish-muddy-waters-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NMC Health down 39% on bearish Muddy Waters report</a></h4><ul><li>Ultra-thinly traded NMC Health plc (<a href='https://seekingalpha.com/symbol/NMHLY' title='NMC Health Plc'>OTCPK:NMHLY</a>) is down <font color=\"red\">39%</font>, albeit on only 1,277 shares, on the heels of a <a href=\"https://www.muddywatersresearch.com/research/nmc/mw-is-short-nmc/\" target=\"_blank\">bearish report</a> from Muddy Waters.</li><li>MW cites suspiciously high purchase prices and capex, earmarks of \"significant fraud,\" exemplified by its $107.4M investment in redeveloping NMC Royal Women's Hospital and its $36.4M purchase of 70% of Premier Care Home Medical and Health Care LLC, both at significant premiums.</li><li>MW also says the company's margins are \"too good to be true,\" citing its underreporting of reimbursement rejections. Related party purchases also appear suspect.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526811\" data-linked=\"NMC Health down 39% on bearish Muddy Waters report\" data-tweet=\"$NMHLY $NMMCF - NMC Health down 39% on bearish Muddy Waters report https://seekingalpha.com/news/3526811-nmc-health-down-39-on-bearish-muddy-waters-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3526811-nmc-health-down-39-on-bearish-muddy-waters-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526800\" data-ts=\"1576594557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526800-freeportplus-1_5-bmo-turns-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport +1.5% as BMO turns bullish</a></h4><ul><li>BMO upgrades Freeport-McMoRan (NYSE:<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a>) from Market Perform to Outperform and lifts the target by $5 to $17. FCX has a Bullish average <a href=\"https://seekingalpha.com/symbol/FCX/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>The firm says FCX's 2020 risks have diminished as the transition from surface to underground at the Grasberg mine is progressing ahead of schedule.</li><li>BMO says investor focus will shift towards 2021 and 2022 valuation metrics, which the firm sees remaining favorable.</li><li>FCX shares are <font color=\"green\">up 1.5%</font> to $13.14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526800\" data-linked=\"Freeport +1.5% as BMO turns bullish\" data-tweet=\"$FCX - Freeport +1.5% as BMO turns bullish https://seekingalpha.com/news/3526800-freeportplus-1_5-bmo-turns-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3526800-freeportplus-1_5-bmo-turns-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526796\" data-ts=\"1576594340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCNNF\" target=\"_blank\">TCNNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526796-fraud-allegations-against-trulieve\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fraud allegations against Trulieve</a></h4><ul><li>\"Why we believe [Trulieve Cannabis] is a fraud,\" goes the title of a new report from Grizzly Research.</li><li>Among the items: Due diligence suggests most of the company's cultivation space comes from hoop houses producing low-quality output prone to infestation and weather damage; ties between the company and FBI probes into corruption in North Florida; the company's initial license approval \"stinks of corruption.\"</li><li><a href=\"https://grizzlyreports.com/trulieve-cannabis-corp-why-we-believe-the-company-is-a-fraud/\" target=\"_blank\">Full report here</a></li><li><a href='https://seekingalpha.com/symbol/TCNNF' title='Trulieve Cannabis Corp.'>OTCPK:TCNNF</a> is<font color=\"red\"> down 2.1%</font> in early action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526796\" data-linked=\"Fraud allegations against Trulieve\" data-tweet=\"$TCNNF - Fraud allegations against Trulieve https://seekingalpha.com/news/3526796-fraud-allegations-against-trulieve?source=tweet\" data-url=\"https://seekingalpha.com/news/3526796-fraud-allegations-against-trulieve\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>173&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526793\" data-ts=\"1576594002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTO\" target=\"_blank\">APTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526793-aptose-up-3-after-pricing-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptose up 3% after pricing stock offering</a></h4><ul><li>Aptose Biosciences (<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color=\"green\">+3.4%</font>) is up out of the gate after pricing its <a href=\"https://seekingalpha.com/pr/17729990-aptose-announces-pricing-of-public-offering-of-common-shares\" target=\"_blank\">public offering</a> of 16,125,000 common shares at $4.00. Underwriters' over-allotment is an additional ~2.4M shares. Closing date is December 19.</li><li>Yesterday's close was $4.43.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526793\" data-linked=\"Aptose up 3% after pricing stock offering\" data-tweet=\"$APTO - Aptose up 3% after pricing stock offering https://seekingalpha.com/news/3526793-aptose-up-3-after-pricing-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3526793-aptose-up-3-after-pricing-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526794\" data-ts=\"1576593893\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526794-pareteumplus-8_6-on-20m-financing-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +8.6% on $20M financing agreement</a></h4><ul><li>Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <a href=\"https://seekingalpha.com/pr/17730093-pareteum-announces-financing-agreement-hoving-partners-for-up-to-20-million\" target=\"_blank\">is offering</a> 255 shares of non-convertible 8% Series C redeemable preferred stock for a purchase price of up to $20M.</li><li>TEUM expects to receive $5M in proceeds from the initial closing rounds, which are expected to be completed by December 20.</li><li>Under the agreement, TEUM may raise up to an additional $15M in proceeds at a purchase price of $100,000 per share.</li><li>The financing deal is with top holder Hoving &amp; Partners.</li><li>TEUM shares are <font color=\"green\">up 8.6%</font> to $0.46.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526794\" data-linked=\"Pareteum +8.6% on $20M financing agreement\" data-tweet=\"$TEUM - Pareteum +8.6% on $20M financing agreement https://seekingalpha.com/news/3526794-pareteumplus-8_6-on-20m-financing-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3526794-pareteumplus-8_6-on-20m-financing-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526786\" data-ts=\"1576593386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOGM\" target=\"_blank\">LOGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526786-logmein-acquired-for-86_05-per-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LogMeIn acquired for $86.05 per share</a></h4><ul><li>LogMeIn (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGM' title='LogMeIn, Inc.'>LOGM</a>) will be acquired by a group led by Francisco Partners and Elliott Management's Evergreen Coast Capital. LogMeIn will become a privately held company.</li><li>The group will pay $86.05 per share in cash, which values LOGM at a $4.3B equity valuation.</li><li>The purchase price represents a 25% premium to LogMeIn's closing price on September 18, the last trading day before the first M&amp;A media report was published.</li><li>The agreement includes a 45-day go-shop period. If LOGM doesn't accept another offer, the deal is expected to close in mid-2020.</li><li>LOGM shares were halted ahead of the announcement.</li><li>Post updated to correct wording of first bullet.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526786\" data-linked=\"LogMeIn acquired for $86.05 per share\" data-tweet=\"$LOGM - LogMeIn acquired for $86.05 per share https://seekingalpha.com/news/3526786-logmein-acquired-for-86_05-per-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3526786-logmein-acquired-for-86_05-per-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526779\" data-ts=\"1576592903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526779-centurylinkminus-1_6-morgan-stanley-turns-cautious-on-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CenturyLink -1.6% as Morgan Stanley turns cautious on sector</a></h4><ul><li>Morgan Stanley downgrades CenturyLink (NYSE:<a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a>) from Overweight to Equal-Weight and trims the target from $16 to $14.80. The company has a Neutral average <a href=\"https://seekingalpha.com/symbol/CTL/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Analyst Simon Flannery has grown more cautious on the telecom services sector due to increasing 2020 headwinds, including regulatory concerns and increased competition as the 5G rollout begins.</li><li>Flannery calls AT&amp;T (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>) and Telephone &amp; Data Systems (NYSE:<a href='https://seekingalpha.com/symbol/TDS' title='Telephone and Data Systems, Inc.'>TDS</a>) among the firm's \"key\" overweight stocks for next year.</li><li>CenturyLink shares are <font color=\"red\">down 1.6%</font> pre-market to $13.37.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526779\" data-linked=\"CenturyLink -1.6% as Morgan Stanley turns cautious on sector\" data-tweet=\"$CTL $T $TDS - CenturyLink -1.6% as Morgan Stanley turns cautious on sector https://seekingalpha.com/news/3526779-centurylinkminus-1_6-morgan-stanley-turns-cautious-on-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3526779-centurylinkminus-1_6-morgan-stanley-turns-cautious-on-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526777\" data-ts=\"1576592680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526777-tge-pcg-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TGE, PCG among premarket gainers</a></h4><ul><li>Tallgrass Energy (NYSE:<a href='https://seekingalpha.com/symbol/TGE' title='Tallgrass Energy, LP'>TGE</a>) <font color=\"green\">+21%</font> on <a href=\"https://seekingalpha.com/news/3526712-tallgrass-energy-accepts-take-private-offer\" target=\"_blank\">accepting</a> take-private offer.</li><li>Gevo (NASDAQ:<a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a>) <font color=\"green\">+19%</font> after entering into an <a href=\"https://seekingalpha.com/pr/17730296-delta-enters-offtake-agreement-gevo-for-10-million-gallons-per-year-of-sustainable-aviation\" target=\"_blank\">offtake agreement</a> with Delta.</li><li>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/news/3526696-immunogen-up-27-premarket-on-accelerated-pathway-for-mirvetuximab-soravtansine\" target=\"_blank\">accelerated</a> pathway for mirvetuximab soravtansine.</li><li>Renewable Energy Group (NASDAQ:<a href='https://seekingalpha.com/symbol/REGI' title='Renewable Energy Group, Inc.'>REGI</a>) <font color=\"green\">+15%</font>.</li><li>Sasol (NYSE:<a href='https://seekingalpha.com/symbol/SSL' title='Sasol Limited'>SSL</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/pr/17729645-sasols-lake-charles-chemicals-project-lccp-ethane-cracker-successfully-replaces-acetylene\" target=\"_blank\">increasing</a> ethylene production rates.</li><li>Boxlight (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight Corporation'>BOXL</a>) <font color=\"green\">+11%</font> on <a href=\"https://seekingalpha.com/pr/17730103-boxlight-receives-1_25-million-follow-on-investment-from-lind-partners\" target=\"_blank\">receiving</a> $1.25M follow-on investment from the Lind Partners.</li><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3526746-jabilplus-9-after-beat-and-raise\" target=\"_blank\">Q1 earnings</a>.</li><li>Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>) <font color=\"green\">+8%</font>.</li><li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3526747-pg-and-e-amends-rsa-to-proceed-settlement-approval-hearing\" target=\"_blank\">amending</a> RSA to proceed with settlement approval hearing.</li><li>Assertio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics, Inc.'>ASRT</a>) <font color=\"green\">+6%</font>.</li><li>Sibanye Gold (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye Gold Limited'>SBGL</a>) <font color=\"green\">+5%</font>.</li><li>Biohaven Pharmaceutical Holding (NYSE:<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/news/3526736-biohaven-pharma-up-8-premarket-on-positive-vazegepant-data\" target=\"_blank\">positive</a> vazegepant data.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526777\" data-linked=\"TGE, PCG among premarket gainers\" data-tweet=\"$TGE $GEVO $IMGN - TGE, PCG among premarket gainers https://seekingalpha.com/news/3526777-tge-pcg-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526777-tge-pcg-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526776\" data-ts=\"1576592651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMS\" target=\"_blank\">ADMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526776-adamas-pharmas-gocovri-meets-endpoint-in-late-stage-ms-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamas Pharma&#39;s Gocovri meets endpoint in late-stage MS study</a></h4><ul><li>Adamas Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a>) <a href=\"https://seekingalpha.com/pr/17730325-adamas-announces-top-line-results-from-inroads-phase-3-trial-of-adsminus-5102-for-multiple\" target=\"_blank\">announces </a>positive results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03436199?lead=adamas+pharmaceuticals&amp;phase=2&amp;draw=2&amp;rank=2\" target=\"_blank\">INROADS</a>, evaluating Gocovri (amantadine) (ADS-5102) in multiple sclerosis &#40;MS&#41; patients with walking impairment.</li><li>The study met the primary endpoint demonstrating a statistically significant improvement in response rate compared to placebo as determined by at least a 20% improvement in walking speed from baseline at week 12 in a Timed 25 Foot Walk. Specifically, patients receiving 274 mg of ADS-5102 each day showed a 21.1% response rate versus 11.3% for control (p=0.01). The response rate was 17.6% in the 137 mg dose arm but the separation from placebo was not statistically valid.</li><li>Neither dose sufficiently separated from placebo on the secondary walking measures.</li><li>On the safety front, the discontinuation rates in the 274 mg and 137 mg arms were 20.5% and 6.4%, respectively, compared to 3.8% in the control arm. The most common (&gt;5%) treatment-related adverse events were peripheral edema, dry mouth, fall, constipation, urinary tract infection and insomnia.</li><li>According to CEO Neil McFarlane, the company will \"fully assess\" the candidate's potential, considering the mixed results, before deciding on next steps.</li><li>The FDA approved Gocovri in August 2017 for Parkinson's disease-related dyskinesia.</li><li>Shares, currently halted, will resume trading at 9:50 am ET.</li><li><strong>Update</strong>: Shares down <font color=\"red\">42%</font> on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526776\" data-linked=\"Adamas Pharma&#39;s Gocovri meets endpoint in late-stage MS study\" data-tweet=\"$ADMS - Adamas Pharma&#39;s Gocovri meets endpoint in late-stage MS study https://seekingalpha.com/news/3526776-adamas-pharmas-gocovri-meets-endpoint-in-late-stage-ms-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3526776-adamas-pharmas-gocovri-meets-endpoint-in-late-stage-ms-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526774\" data-ts=\"1576592401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GES\" target=\"_blank\">GES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526774-guessplus-6-after-cowen-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guess +6% after Cowen nod</a></h4><ul> <li>Shares of Guess (NYSE:<a href='https://seekingalpha.com/symbol/GES' title='Guess&#39;, Inc.'>GES</a>) race higher after the retailer is upgraded by Cowen to an Outperform rating from Market Perform.</li> <li>Cowen sees the new emphasis by Guess on improving free cash flow and profit margin as a positive.</li> <li>The firm assigns a price target of $26 to Guess vs. the <a href=\"https://seekingalpha.com/symbol/GES/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $21.33.</li> <li>Guess <font color=\"green\">+5.95%</font> premarket to $20.89 vs. the 52-week trading range of $13.34 to $23.28.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3526774\" data-linked=\"Guess +6% after Cowen nod\" data-tweet=\"$GES - Guess +6% after Cowen nod https://seekingalpha.com/news/3526774-guessplus-6-after-cowen-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3526774-guessplus-6-after-cowen-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526773\" data-ts=\"1576592353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526773-synapticsminus-6-rosenblatt-turns-bearish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics -6% as Rosenblatt turns bearish</a></h4><ul><li>Rosenblatt downgrades Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) from Neutral to Sell with a $45 target. The company has a Neutral average <a href=\"https://seekingalpha.com/symbol/SYNA/ratings/sell-side-ratings?s=syna\" target=\"_blank\">Sell Side rating</a>.</li><li>The firm says SYNA is losing market share in China as Huawei moves to support non-U.S. suppliers.</li><li>Rosenblatt expects revenue to \"significantly decline\" next year. Even if SYNA did <a href=\"https://seekingalpha.com/news/3526231-rosenblatt-doesnt-expect-apple-win-for-synaptics\" target=\"_blank\">win market share</a> at Apple, the gain wouldn't be enough to offset the losses in the other businesses.</li><li>SYNA shares are <font color=\"red\">down 6.2%</font> pre-market to $61.71.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526773\" data-linked=\"Synaptics -6% as Rosenblatt turns bearish\" data-tweet=\"$SYNA - Synaptics -6% as Rosenblatt turns bearish https://seekingalpha.com/news/3526773-synapticsminus-6-rosenblatt-turns-bearish?source=tweet\" data-url=\"https://seekingalpha.com/news/3526773-synapticsminus-6-rosenblatt-turns-bearish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526770\" data-ts=\"1576592010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YUM\" target=\"_blank\">YUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526770-argus-cools-on-yum-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argus cools on Yum Brands</a></h4><ul> <li>Argus lowers Yum Brands (NYSE:<a href='https://seekingalpha.com/symbol/YUM' title='YUM! Brands, Inc.'>YUM</a>) to a Hold rating from Buy on concerns comparable sales growth will slow in Q4 and into 2020.</li> <li>\"We believe, as U.S. competition intensifies, results at KFC and Pizza Hut will come under pressure. Pizza Hut's revenue will likely be hurt by competition from such delivery services as GrubHub and UberEats and difficulties related to its greater emphasis on off-premise orders (carryout and delivery). As such, we expect Pizza Hut's recent flat same-store sales to continue throughout 2020. KFC's results are likely to be hurt by competition from Chick-fil-A and Popeyes, particularly the latter which recently rereleased its popular chicken sandwich. Despite tough comparisons, we expect Taco Bell to report mid-single-digit same-store sales growth and increase market share in the U.S. and overseas.\"</li> <li>Analyst John Staszak and team lower the 2019 EPS estimate on Yum to $3.75 from $3.80 and 2020 EPS estimate to $4.20 from $4.30.</li><li>The average sell-side rating on Yum leans Bullish, while the <a href=\"https://seekingalpha.com/symbol/YUM/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is flashing Neutral.</li> <li>Shares of Yum are <font color=\"red\">down 0.84%</font> premarket to $100.04.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526770\" data-linked=\"Argus cools on Yum Brands\" data-tweet=\"$YUM - Argus cools on Yum Brands https://seekingalpha.com/news/3526770-argus-cools-on-yum-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3526770-argus-cools-on-yum-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526769\" data-ts=\"1576591964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526769-ul-clvs-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UL, CLVS among premarket losers</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"red\">-37%</font> on <a href=\"https://seekingalpha.com/news/3526749-proteostasis-down-34-on-mixed-results-in-mid-stage-cf-study\" target=\"_blank\">mixed results</a> in mid-stage CF study.</li><li>MEI Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/MEIP' title='MEI Pharma, Inc.'>MEIP</a>) <font color=\"red\">-28%</font> on <a href=\"https://seekingalpha.com/news/3526741-mei-pharma-down-27-premarket-on-pricing-stock-offering\" target=\"_blank\">pricing</a> stock offering.</li><li>VistaGen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a>) <font color=\"red\">-9%</font>.</li><li>The Unilever Group (NYSE:<a href='https://seekingalpha.com/symbol/UL' title='The Unilever Group'>UL</a>) <font color=\"red\">-8%</font> on expected <a href=\"https://seekingalpha.com/news/3526673-unilever-sales-growth-will-miss-forecasts\" target=\"_blank\">forecasts miss</a>.</li><li>Lloyds Banking Group (NYSE:<a href='https://seekingalpha.com/symbol/LYG' title='Lloyds Banking Group plc'>LYG</a>) <font color=\"red\">-8%</font>.</li><li>The Unilever Group (NYSE:<a href='https://seekingalpha.com/symbol/UN' title='The Unilever Group'>UN</a>) <font color=\"red\">-7%</font> on expected <a href=\"https://seekingalpha.com/news/3526673-unilever-sales-growth-will-miss-forecasts\" target=\"_blank\">forecasts miss</a>.</li><li>RiceBran Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/pr/17730088-ricebran-technologies-announces-pricing-of-public-offering-of-common-stock\" target=\"_blank\">pricing</a> common stock offering.</li><li>Tonix Pharmaceuticals Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <font color=\"red\">-6%</font>.</li><li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology, Inc.'>CLVS</a>) <font color=\"red\">-5%</font> after <a href=\"https://seekingalpha.com/news/3526665-clovis-oncology-files-for-250m-mixed-shelf-shares-down-12\" target=\"_blank\">filing</a> for $250M mixed shelf.</li><li>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-6%</font>.</li><li>The Royal Bank of Scotland Group (NYSE:<a href='https://seekingalpha.com/symbol/RBS' title='The Royal Bank of Scotland Group plc'>RBS</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526769\" data-linked=\"UL, CLVS among premarket losers\" data-tweet=\"$PTI $MEIP $VTGN - UL, CLVS among premarket losers https://seekingalpha.com/news/3526769-ul-clvs-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526769-ul-clvs-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526768\" data-ts=\"1576591958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOM\" target=\"_blank\">BOOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526768-dmc-global-lowers-q4-revenue-and-fy19-eps-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DMC Global lowers Q4 revenue and FY19 EPS guidance</a></h4><ul><li>DMC Global (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOM' title='DMC Global Inc.'>BOOM</a>) now <a href=\"https://seekingalpha.com/pr/17729723-dmc-global-revises-fourth-quarter-sales-forecast\" target=\"_blank\">expects</a> Q4 revenue in the range of $82M to 86M (prior forecast $92M to $97M) vs. a consensus $94.02M.</li><li>Q4 sales at DynaEnergetics are expected in a range of $62M to $64M (prior forecast $72M to $75M); Q4 sales at NobelClad, DMC\u2019s composite metals business, remain in the previously forecasted range of $20M to $22M.</li><li>BOOM expects Q4 adjusted EBITDA to be $14.0M to $15.0M (prior guidance $17.5M to $20M).</li><li>FY19 Non-GAAP EPS expected to be in a range of $3.50 to $3.60 (prior guidance $3.65 to $3.80) vs. a consensus of $3.71.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526768\" data-linked=\"DMC Global lowers Q4 revenue and FY19 EPS guidance\" data-tweet=\"$BOOM - DMC Global lowers Q4 revenue and FY19 EPS guidance https://seekingalpha.com/news/3526768-dmc-global-lowers-q4-revenue-and-fy19-eps-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3526768-dmc-global-lowers-q4-revenue-and-fy19-eps-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526762\" data-ts=\"1576591158\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMS\" target=\"_blank\">ADMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526762-adamas-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamas shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Adamas Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526762\" data-linked=\"Adamas shares halted pending news\" data-tweet=\"$ADMS - Adamas shares halted pending news https://seekingalpha.com/news/3526762-adamas-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3526762-adamas-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526760\" data-ts=\"1576591104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PI\" target=\"_blank\">PI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526760-needham-bullish-on-impinj-market-strength-piplus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham bullish on Impinj market strength; PI +4%</a></h4><ul><li>Needham upgrades Impinj (NASDAQ:<a href='https://seekingalpha.com/symbol/PI' title='Impinj, Inc.'>PI</a>) from Hold to Buy with a $32 target, forecasting 2020 upside from new products and RFID market strength.</li><li>Analyst James Ricchiuti says the overall RFID market \"continues to show healthy growth,\" which should drive PI strength through 2021.</li><li>PI shares are <font color=\"green\">up 4.1%</font> pre-market to $27.25.</li><li>Impinj has a Bullish average <a href=\"https://seekingalpha.com/symbol/PI/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526760\" data-linked=\"Needham bullish on Impinj market strength; PI +4%\" data-tweet=\"$PI - Needham bullish on Impinj market strength; PI +4% https://seekingalpha.com/news/3526760-needham-bullish-on-impinj-market-strength-piplus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3526760-needham-bullish-on-impinj-market-strength-piplus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526757\" data-ts=\"1576590847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526757-morgan-stanley-sees-15-upside-in-amgen-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley sees 15% upside in Amgen in premarket analyst action</a></h4><ul><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) resumed with Overweight rating and $280 (15% upside) price target at Morgan Stanley.</li><li>Hill-Rom Holdings (NYSE:<a href='https://seekingalpha.com/symbol/HRC' title='Hill-Rom Holdings, Inc.'>HRC</a>) upgraded to Overweight with a $138 (25% upside) price target at Morgan Stanley.</li><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) upgraded to Overweight with a $170 (20% upside) price target at Morgan Stanley. Shares up <font color=\"green\">1% </font>premarket.</li><li>MedMen Enterprises (MMEN CN) upgraded to Market Perform at Cowen and Company.</li><li>Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>) downgraded to Equal Weight with a $128 (15% upside) price target at Morgan Stanley. Shares down <font color=\"red\">1%</font> premarket.</li><li>Baxter International (NYSE:<a href='https://seekingalpha.com/symbol/BAX' title='Baxter International Inc.'>BAX</a>) downgraded to Equal Weight with an $88 (5% upside) price target at Morgan Stanley. Shares down <font color=\"red\">1%</font> premarket.</li><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos NV'>GLPG</a>) downgraded to Equal Weight at Morgan Stanley. Shares up <font color=\"green\">1%</font> premarket.</li><li>Kala Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KALA' title='Kala Pharmaceuticals, Inc.'>KALA</a>) downgraded to Neutral at BofA Merrill Lynch. Shares down <font color=\"red\">6%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526757\" data-linked=\"Morgan Stanley sees 15% upside in Amgen in premarket analyst action\" data-tweet=\"$AMGN $HRC $JNJ - Morgan Stanley sees 15% upside in Amgen in premarket analyst action https://seekingalpha.com/news/3526757-morgan-stanley-sees-15-upside-in-amgen-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3526757-morgan-stanley-sees-15-upside-in-amgen-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526754\" data-ts=\"1576590306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526754-interpace-bio-issues-new-draft-lcd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace Bio issues new draft LCD</a></h4><ul> <li>Interpace Biosciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Biosciences, Inc.'>IDXG</a>) Medicare Administrative Contractor &#40;MAC&#41; <a href=\"https://seekingalpha.com/pr/17729766-interpace-biosciences-announces-new-draft-lcd-and-reimbursement-for-proprietary-thyroid-assay\" target=\"_blank\">announces</a> a new draft local coverage determination &#40;LCD&#41; for the Company\u2019s ThyGeNEXT test, representing an increase of ~$2,400 per assay over previous reimbursement coverage.</li><li>This increase reflects the expansion of the ThyGeNEXT panel to aid in identifying the appropriate patients for surgery.</li>     <li>Prior to the new LCD code (81455) becoming effective, it was subject to a public comment period, which ended December 15, 2019, and is now subject to an analysis and review period by MAC\u2019s Medical Directors.</li><li>Final approval is expected during Q1 2020.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3526754\" data-linked=\"Interpace Bio issues new draft LCD\" data-tweet=\"$IDXG - Interpace Bio issues new draft LCD https://seekingalpha.com/news/3526754-interpace-bio-issues-new-draft-lcd?source=tweet\" data-url=\"https://seekingalpha.com/news/3526754-interpace-bio-issues-new-draft-lcd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526749\" data-ts=\"1576589952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526749-proteostasis-down-34-on-mixed-results-in-mid-stage-cf-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis down 34% on mixed results in mid-stage CF study</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) slumps <font color=\"red\">34%</font> premarket on robust volume on the heels of <a href=\"https://seekingalpha.com/pr/17729867-proteostasis-therapeutics-announces-positive-phase-2-topline-results-from-proprietary-cftr\" target=\"_blank\">topline results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03500263?lead=proteostasis&amp;phase=1&amp;draw=2&amp;rank=2\" target=\"_blank\">Phase 2 clinical trial</a> evaluating its CFTR modulator combinations in cystic fibrosis &#40;CF&#41; patients.</li><li>The study assessed dirocaftor (PTI-808) and posenacaftor (PTI-801) with or without nesolicaftor (PTI-428) in 28 F508del homozygous and 40 F508del heterozygous subjects.</li><li>On the plus side, homozygous patients receiving the triple combo (n=11) experienced a mean absolute 8% relative improvement in lung function compared to pooled placebo at day 28 (p&lt;=0.01). The treatment effect on lung function and sweat chloride concentration was higher for the triplet therapy versus the doublet (dirocafter + posenacaftor) but specific values are not provided.</li><li>In the heterozygous group, the results were mixed. The mean relative change in lung function for the triplet therapy was not statistically significant, but the change in sweat chloride concentration was.</li><li>The company plans to launch a Phase 3 study, MORE, in homozygous CF patients in 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526749\" data-linked=\"Proteostasis down 34% on mixed results in mid-stage CF study\" data-tweet=\"$PTI - Proteostasis down 34% on mixed results in mid-stage CF study https://seekingalpha.com/news/3526749-proteostasis-down-34-on-mixed-results-in-mid-stage-cf-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3526749-proteostasis-down-34-on-mixed-results-in-mid-stage-cf-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526748\" data-ts=\"1576589847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLPH\" target=\"_blank\">BLPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526748-bellerophonplus-36-premarket-on-positive-results-from-ino-pf-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellerophon +36% premarket on positive results from iNO-PF study</a></h4><ul> <li>Bellerophon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BLPH' title='Bellerophon Therapeutics, Inc.'>BLPH</a>) is up <font color=\"green\">36%</font> on the heels of <a href=\"https://seekingalpha.com/pr/17729792-bellerophon-announces-positive-top-line-results-from-cohort-2-of-phase-2-3-study-of-inopulse\" target=\"_blank\">positive top-line results</a> from Cohort 2 of its ongoing Phase 2/3 study (iNO-PF) of INOpulse for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD).</li>  <li>Subjects in Cohort 2 of iNO-PF treated with iNO45 (45 mcg/kg IBW/hr) demonstrated statistically significant improvement in moderate to vigorous physical activity &#40;MVPA&#41;, defined as walking, climbing stairs, yard work, and similar activities, versus placebo.</li><li>The improvements in MVPA were underscored by benefits shown in other actigraphy parameters, as well as patient reported outcomes.</li><li>The Phase 3 study is expected to initiate in Q1 2020.</li>    <li>The Company has also entered into an agreement for a $10M convertible financing facility, led by existing institutional investors.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3526748\" data-linked=\"Bellerophon +36% premarket on positive results from iNO-PF study\" data-tweet=\"$BLPH - Bellerophon +36% premarket on positive results from iNO-PF study https://seekingalpha.com/news/3526748-bellerophonplus-36-premarket-on-positive-results-from-ino-pf-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3526748-bellerophonplus-36-premarket-on-positive-results-from-ino-pf-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526747\" data-ts=\"1576589590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526747-pg-and-e-amends-rsa-to-proceed-settlement-approval-hearing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E amends RSA to proceed with settlement approval hearing</a></h4><ul><li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>)<a href=\"https://seekingalpha.com/pr/17729629-pg-and-e-announces-amendment-to-restructuring-support-agreement-individual-wildfire-victims\" target=\"_blank\"> amends its restructuring support agreement</a> with certain representatives of the wildfire victims to reaffirm the parties' support of the $13.5B settlement.</li><li>The amendments to the Tort Claimants RSA eliminates the provision that would automatically terminate the Tort Claimants RSA if California's governor tells PG&amp;E that its Chapter 11 plan doesn't comply with California's Assembly Bill 1054 and the plan isn't modified in a manner acceptable to the governor by Dec. 17, 2019.</li><li>The parties intend to proceed with the Tort Claimants RSA approval hearing before the Bankruptcy Court today.</li><li>The company said it fully intends to comply with the provisions of AB 1054 and will continue to address the concerns in the letter to the company from the governor dated Dec. 13, 2019.</li><li>PCG <font color=\"green\">gains 5.2%</font> in premarket trading, reversing some of the 14% decline in trading yesterday.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526308-newsom-rejects-pg-and-e-bankruptcy-plan\" target=\"_blank\">Newsom rejects PG&amp;E bankruptcy plan</a> (Dec. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526747\" data-linked=\"PG&amp;E amends RSA to proceed with settlement approval hearing\" data-tweet=\"$PCG - PG&amp;E amends RSA to proceed with settlement approval hearing https://seekingalpha.com/news/3526747-pg-and-e-amends-rsa-to-proceed-settlement-approval-hearing?source=tweet\" data-url=\"https://seekingalpha.com/news/3526747-pg-and-e-amends-rsa-to-proceed-settlement-approval-hearing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526746\" data-ts=\"1576589581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526746-jabilplus-9-after-beat-and-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil +9% after beat-and-raise</a></h4><ul><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) <font color=\"green\">+9%</font> reports <a href=\"https://seekingalpha.com/news/3526729-jabil-eps-beats-0_10-beats-on-revenue\" target=\"_blank\">Q1 beats</a> with revenue up 15% Y/Y. The in-line Q2 outlook sees revenue of $6.0-6.2B and EPS of  $0.62-0.82.</li><li>The company raises its FY20 guidance to $26.7B in revenue (was: $26B; consensus: $26.08B) and $3.60 EPS (was: $3.45; consensus: $3.44).</li><li>In Q1, Electronics Manufacturing contributed $4.4B in revenue and Diversified Manufacturing totaled $3.09B.</li><li>Gross margin was 7.38% compared to the 7.8% consensus.</li><li>Earnings call starts at 8:30 AM with a webcast<a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.jabil.com&amp;esheet=52147931&amp;newsitemid=20191217005139&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestors.jabil.com&amp;index=1&amp;md5=03056e523ea7d4ddfff5d6ebe1026158\" target=\"_blank\"> here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17729936-jabil-delivers-record-quarterly-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526746\" data-linked=\"Jabil +9% after beat-and-raise\" data-tweet=\"$JBL - Jabil +9% after beat-and-raise https://seekingalpha.com/news/3526746-jabilplus-9-after-beat-and-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3526746-jabilplus-9-after-beat-and-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526743\" data-ts=\"1576589275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLSN\" target=\"_blank\">NLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526743-nielsenminus-3-after-barclays-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nielsen -3% after Barclays cut</a></h4><ul> <li>Nielsen Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NLSN' title='Nielsen Holdings plc'>NLSN</a>) slumps in early trading after Barclays lowers its rating to Underweight from Equal-weight.</li> <li>The firm assigns a price target of $20 to Nielsen vs. the average sell-side PT of <a href=\"https://seekingalpha.com/symbol/NLSN/ratings/sell-side-ratings\" target=\"_blank\">$25.24</a>.</li> <li>Shares of Nielsen are <font color=\"red\">down 3.35%</font> premarket to $19.31.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526743\" data-linked=\"Nielsen -3% after Barclays cut\" data-tweet=\"$NLSN - Nielsen -3% after Barclays cut https://seekingalpha.com/news/3526743-nielsenminus-3-after-barclays-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3526743-nielsenminus-3-after-barclays-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526741\" data-ts=\"1576589078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEIP\" target=\"_blank\">MEIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526741-mei-pharma-down-27-premarket-on-pricing-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MEI Pharma down 27% premarket on pricing stock offering</a></h4><ul> <li>MEI Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/MEIP' title='MEI Pharma, Inc.'>MEIP</a>) has <a href=\"https://seekingalpha.com/pr/17730018-mei-pharma-announces-pricing-of-public-offering-of-common-stock\" target=\"_blank\">priced</a> its public offering of 28,125,000 common shares at $1.60 per share for total gross proceeds of ~$45M.</li><li>Underwriters' over-allotment is an additional 4,218,750 shares.</li> <li>Net proceeds will be used to progress clinical development of programs, for working capital and other general corporate purposes.</li><li>Closing date is December 19.</li><li>Shares are down <font color=\"red\">27%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3526741\" data-linked=\"MEI Pharma down 27% premarket on pricing stock offering\" data-tweet=\"$MEIP - MEI Pharma down 27% premarket on pricing stock offering https://seekingalpha.com/news/3526741-mei-pharma-down-27-premarket-on-pricing-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3526741-mei-pharma-down-27-premarket-on-pricing-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526736\" data-ts=\"1576588315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHVN\" target=\"_blank\">BHVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526736-biohaven-pharma-up-8-premarket-on-positive-vazegepant-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biohaven Pharma up 8% premarket on positive vazegepant data</a></h4><ul><li>Biohaven Pharmaceutical Holding Company Ltd. (NYSE:<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a>) is up <font color=\"green\">8%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17729869-biohaven-achieves-positive-topline-results-in-pivotal-phase-2-3-study-of-vazegepant-first-and\" target=\"_blank\">positive topline results</a> from a Phase 2/3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03872453?term=NCT03872453&amp;draw=2&amp;rank=1\" target=\"_blank\">BHV3500-201</a>, evaluating intranasal vazegepant for the acute treatment of migraine.</li><li>The 10 mg and 20 mg dose arms met the co-primary endpoints of pain freedom and freedom from the most bothersome symptom at hour 2 compared to placebo. The 5 mg dose arm did not.</li><li>Key secondary endpoints were also met.</li><li>On the safety front, the most common adverse events were dysgeusia (distortion in sense of taste) (13.5% - 16.1% vs. 3.5% for control), and nasal discomfort (1.3 - 5.2% vs. 0.2%).</li><li>Additional data will be submitted for presentation at medical conferences in 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526736\" data-linked=\"Biohaven Pharma up 8% premarket on positive vazegepant data\" data-tweet=\"$BHVN - Biohaven Pharma up 8% premarket on positive vazegepant data https://seekingalpha.com/news/3526736-biohaven-pharma-up-8-premarket-on-positive-vazegepant-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3526736-biohaven-pharma-up-8-premarket-on-positive-vazegepant-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526729\" data-ts=\"1576587718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526729-jabil-eps-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil EPS beats by $0.10, beats on revenue</a></h4><ul><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>): Q1 Non-GAAP EPS of $1.05 <font color=\"green\">beats by $0.10</font>; GAAP EPS of $0.26 <font color=\"red\">misses by $0.36</font>.</li><li>Revenue of $7.51B (+15.4% Y/Y) <font color=\"green\">beats by $560M</font>.</li><li>Shares <font color=\"green\">+2.58%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17729936-jabil-delivers-record-quarterly-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526729\" data-linked=\"Jabil EPS beats by $0.10, beats on revenue\" data-tweet=\"$JBL - Jabil EPS beats by $0.10, beats on revenue https://seekingalpha.com/news/3526729-jabil-eps-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3526729-jabil-eps-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526724\" data-ts=\"1576587500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526724-alnylams-lumasiran-successful-in-late-stage-ph1-study-shares-up-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam&#39;s lumasiran successful in late-stage PH1 study; shares up 6% premarket</a></h4><ul><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) is up <font color=\"green\">6%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17729769-alnylam-reports-positive-topline-results-from-illuminate-phase-3-study-of-lumasiran-for\" target=\"_blank\">positive results</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03681184?term=illuminate-A&amp;draw=2&amp;rank=1\" target=\"_blank\">ILLUMINATE-A</a>, evaluating lumasiran in patients with primary hyperoxaluria type 1 (PH1), a rare inherited disorder characterized by kidney and bladder stones caused by excess levels of oxalate in the kidneys and urinary tract.</li><li>The 30-subject study met the primary and all secondary endpoints.</li><li>Results from another Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03905694?term=illuminate-b&amp;draw=2&amp;rank=1\" target=\"_blank\">ILLUMINATE-B</a>, should be available in mid-2020. A third Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT04152200?term=illuminate-c&amp;draw=2&amp;rank=1\" target=\"_blank\">ILLUMINATE-C</a>, should launch in 2021.</li><li>The company plans to file a marketing applications in the U.S. and Europe in early 2020.</li><li>Lumasiran is designed to reduce oxalate in the body by reducing the levels of an enzyme called glycolate oxidase which depletes the substrate necessary for oxalate production. It has Breakthrough Therapy status in the U.S. and PRIME status in Europe for the indication.</li><li>A conference call will begin momentarily.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526724\" data-linked=\"Alnylam&#39;s lumasiran successful in late-stage PH1 study; shares up 6% premarket\" data-tweet=\"$ALNY - Alnylam&#39;s lumasiran successful in late-stage PH1 study; shares up 6% premarket https://seekingalpha.com/news/3526724-alnylams-lumasiran-successful-in-late-stage-ph1-study-shares-up-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3526724-alnylams-lumasiran-successful-in-late-stage-ph1-study-shares-up-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526719\" data-ts=\"1576586842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCCL\" target=\"_blank\">CCCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526719-china-ceramics-tumbles-after-pricing-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Ceramics tumbles after pricing offering</a></h4><ul><li>China Ceramics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a>) <font color=\"red\">-21.7%</font> premarket after <a href=\"https://seekingalpha.com/pr/17729410-china-ceramics-announces-pricing-of-registered-direct-public-offering\" target=\"_blank\">entering</a> into a definitive agreement with certain institutional investors for a registered direct offering of securities with gross proceeds of approximately $900K.</li><li>In connection with the offering, the company will issue 1.2M registered common shares at a purchase price of $0.75 per share.</li><li>The closing of the offering is expected to take place on or about December 18, 2019 subject to the satisfaction of customary closing conditions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526719\" data-linked=\"China Ceramics tumbles after pricing offering\" data-tweet=\"$CCCL - China Ceramics tumbles after pricing offering https://seekingalpha.com/news/3526719-china-ceramics-tumbles-after-pricing-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3526719-china-ceramics-tumbles-after-pricing-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526706\" data-ts=\"1576585641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526706-micronplus-1_4-wedbush-forecasts-memory-improvement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron +1.4% as Wedbush forecasts memory improvement</a></h4><ul><li>Wedbush raises Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) from Neutral to Outperform and increases the target from $44 to $65, citing \"an improving memory cycle.\" MU has a Bullish average <a href=\"https://seekingalpha.com/symbol/MU/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Analyst Matt Bryson is \"seeing the first signs of improving DRAM pricing,\" and NAND pricing \"should inflect upwards\" in Q1. He says demand for both NAND and DRAM should accelerate through next year.</li><li>Micron reports earnings tomorrow, but Wedbush doesn't expect \"meaningful upside\" in the report.</li><li>MU shares are <font color=\"green\">up 1.4%</font> pre-market to $53.68.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526706\" data-linked=\"Micron +1.4% as Wedbush forecasts memory improvement\" data-tweet=\"$MU - Micron +1.4% as Wedbush forecasts memory improvement https://seekingalpha.com/news/3526706-micronplus-1_4-wedbush-forecasts-memory-improvement?source=tweet\" data-url=\"https://seekingalpha.com/news/3526706-micronplus-1_4-wedbush-forecasts-memory-improvement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526696\" data-ts=\"1576584599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGN\" target=\"_blank\">IMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526696-immunogen-up-27-premarket-on-accelerated-pathway-for-mirvetuximab-soravtansine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmunoGen up 27% premarket on accelerated pathway for mirvetuximab soravtansine</a></h4><ul> <li>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) <a href=\"https://seekingalpha.com/pr/17729748-immunogen-announces-accelerated-approval-pathway-for-mirvetuximab-soravtansine-in-ovarian\" target=\"_blank\">announces</a> that the FDA has advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval for mirvetuximab soravtansine.</li><li>Based on this guidance, the company will initiate SORAYA, a trial to evaluate mirvetuximab monotherapy in women with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).</li> <li>The  Company anticipates enrolling first patient in the study in next quarter with top-line data expected in mid-2021.</li>  <li>The trial will enroll approx. 100 patients. The primary endpoint is overall response rate by investigator assessment and the key secondary endpoint is duration of response.</li><li>Shares are up <font color=\"green\">27%</font> premarket.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3526696\" data-linked=\"ImmunoGen up 27% premarket on accelerated pathway for mirvetuximab soravtansine\" data-tweet=\"$IMGN - ImmunoGen up 27% premarket on accelerated pathway for mirvetuximab soravtansine https://seekingalpha.com/news/3526696-immunogen-up-27-premarket-on-accelerated-pathway-for-mirvetuximab-soravtansine?source=tweet\" data-url=\"https://seekingalpha.com/news/3526696-immunogen-up-27-premarket-on-accelerated-pathway-for-mirvetuximab-soravtansine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526673\" data-ts=\"1576573873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UN\" target=\"_blank\">UN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526673-unilever-sales-growth-will-miss-forecasts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unilever sales growth will miss forecasts</a></h4><ul><li>Like other consumer goods companies, Unilever (NYSE:<a href='https://seekingalpha.com/symbol/UN' title='The Unilever Group'>UN</a>) has struggled to keep up with shoppers turning to fresher foods, niche brands or vegan trends.</li><li>Sales gains are now seen at slightly below guidance for 2019, and underlying growth will be in the lower half of a multiyear range of 3% to 5% in 2020, <a href=\"https://www.bloomberg.com/news/articles/2019-12-17/unilever-sales-growth-to-miss-guidance-on-slump-in-south-asia\" target=\"_blank\">according</a> to the company, which blamed a slowdown in South Asia and weakness in North America.</li><li>Analysts at RBC Europe said the new forecast implies Q4 growth will be the weakest in more than a decade.</li><li>UN <font color=\"red\">-6.1%</font>; <a href='https://seekingalpha.com/symbol/UL' title='The Unilever Group'>UL</a> <font color=\"red\">-5.8%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3526673\" data-linked=\"Unilever sales growth will miss forecasts\" data-tweet=\"$UN $UL - Unilever sales growth will miss forecasts https://seekingalpha.com/news/3526673-unilever-sales-growth-will-miss-forecasts?source=tweet\" data-url=\"https://seekingalpha.com/news/3526673-unilever-sales-growth-will-miss-forecasts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526672\" data-ts=\"1576573008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EWU\" target=\"_blank\">EWU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526672-pound-slumps-on-brexit-deadline-pledge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pound slumps on Brexit deadline pledge</a></h4><ul><li>The sterling honeymoon has come to an end after the currency dropped by the most since last July, <font color=\"red\">tumbling 1.1%</font> to $1.3188.</li><li>Threat of a no-deal split... Legislation from Prime Minister Boris Johnson will <a href=\"https://www.bloomberg.com/news/articles/2019-12-17/pound-slides-on-reports-johnson-will-block-further-brexit-delay?srnd=premium\" target=\"_blank\">include</a> text that guarantees the Brexit transition phase isn't extended beyond December 2020, even if no new trade terms have been secured.</li><li>The pound had climbed to as high as $1.3514 on Friday as the Tories swept to victory, fueling optimism there would be a speedy resolution to the Brexit deadlock.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>, <a href='https://seekingalpha.com/symbol/FXB' title='Invesco CurrencyShares British Pound Sterling Trust ETF'>FXB</a>, <a href='https://seekingalpha.com/symbol/GBB' title='iPath GBP/USD Exchange Rate ETN'>OTC:GBB</a>, <a href='https://seekingalpha.com/symbol/EWUS' title='iShares Trust - iShares MSCI United Kingdom Small-Cap ETF'>EWUS</a>, <a href='https://seekingalpha.com/symbol/FKU' title='First Trust United Kingdom AlphaDex ETF'>FKU</a>, <a href='https://seekingalpha.com/symbol/DGBP' title='VelocityShares Daily 4X Long USD vs. GBP ETN'>DGBP</a>, <a href='https://seekingalpha.com/symbol/HEWU' title='iShares Currency Hedged MSCI United Kingdom ETF'>HEWU</a>, <a href='https://seekingalpha.com/symbol/FLGB' title='Franklin Templeton ETF Trust - Franklin FTSE United Kingdom ETF'>FLGB</a>, <a href='https://seekingalpha.com/symbol/UGBP' title='VelocityShares Daily 4X Long GBP vs. USD ETN'>UGBP</a>, <a href='https://seekingalpha.com/symbol/ZGBR' title='SPDR Index Shares Funds - SPDR Solactive United Kingdom ETF'>ZGBR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526672\" data-linked=\"Pound slumps on Brexit deadline pledge\" data-tweet=\"$EWU $FXB $GBB - Pound slumps on Brexit deadline pledge https://seekingalpha.com/news/3526672-pound-slumps-on-brexit-deadline-pledge?source=tweet\" data-url=\"https://seekingalpha.com/news/3526672-pound-slumps-on-brexit-deadline-pledge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":65,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}